Abbott reported that Diagnostics sales jumped 42% in Q2 to $3.09 billion, driven largely by its March acquisition of Exact Sciences. The company said overall Q2 sales rose to $12.59 billion, beating consensus estimates, with Abbott also raising 2026 comparable sales and adjusted EPS guidance. Within Diagnostics, Abbott said core laboratory revenue increased while rapid/molecular diagnostics declined year over year, and it began reporting cancer diagnostics sales as a separate line item in the quarter following the Exact Sciences integration. Abbott’s guidance update and segment reporting changes underscore how quickly the Exact Sciences deal is reshaping the company’s diagnostics structure and near-term growth narrative.